Active ingredient: Hydrocortisone

advertisement
How old is patient?

Hydrocortisone uses


1 INDICATIONS AND USAGE

hydrocortisone® (hydrocortisone probutate) Cream, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 18 years of age or older.

PANDEL® (hydrocortisone probutate) Cream, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 18 years of age or older.

2 DOSAGE AND ADMINISTRATION

Apply a thin film of hydrocortisone to the affected area once or twice a day depending on the severity of the condition. Massage gently until the medication disappears.

Occlusive dressings may be used for the management of refractory lesions of psoriasis and other deep-seated dermatoses, such as localized neurodermatitis (lichen simplex chronicus).

Discontinue hydrocortisone when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.

Do not use hydrocortisone with occlusive dressings unless directed by the physician. Do not apply hydrocortisone in the diaper area, as diapers or plastic pants may constitute occlusive dressings.

- For topical use.

- Apply a thin film to the affected skin areas once daily or twice a day.

- Discontinue therapy when control is achieved.

- If no improvement is seen within 2 weeks, reassess diagnosis.

- Do not use with occlusive dressings unless directed by a physician.

3 DOSAGE FORMS AND STRENGTHS

Cream, 0.1%. Each gram of hydrocortisone contains 1 mg of hydrocortisone probutate in a cream base.

Cream, 0.1%.

advertisement

4 CONTRAINDICATIONS

None.

None.

5 WARNINGS AND PRECAUTIONS

- hydrocortisone can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency during or after treatment.

- Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can result from systemic absorption of topical corticosteroids. (5.1)

- Use of topical corticosteroids may require periodic evaluation for HPA axis suppression. (5.1)

- High potency corticosteroids, large treatment surface area, prolong use, use of occlusion dressings, altered skin barrier, liver failure and young age may predispose patients to HPA axis suppression. (5.1)

- Modify use if HPA axis suppression develops. (5.1)

- Pediatric patients may be more susceptible to systemic toxicity. (5.1, 8.4)

5.1 Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression and Other Unwanted Systemic Glucocorticoid Effects

hydrocortisone can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. This may occur during or after withdrawal of treatment. Factors that predispose to HPA axis suppression include the use of high-potency corticosteroids, large treatment surface areas, prolonged use, use of occlusive dressings, altered skin barrier, liver failure, and young age.

Use of topical corticosteroids may require periodic evaluation for HPA axis suppression. Evaluation for HPA axis suppression may be done by using the adrenocorticotropic hormone (ACTH) stimulation test.

If HPA axis suppression is documented, gradually withdraw the drug, reduce the frequency of application, or substitute with a less potent corticosteroid. If signs and symptoms of steroid withdrawal occur, supplemental systemic corticosteroids may be required. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug.

In a trial including 15 evaluable subjects 18 years of age or older with psoriasis or atopic dermatitis affecting more than 20% of body surface area, 1 subject (6.7%) had ACTH stimulation test results suggestive of adrenal suppression after treatment with hydrocortisone twice daily for 21 days. Recovery of HPA axis suppression for this subject is unknown [see Clinical Pharmacology ( 12.2 )].

Systemic effects of topical corticosteroids may also manifest as Cushing’s syndrome, hyperglycemia, and unmasking latent diabetes mellitus.

Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA-axis suppression.

Pediatric patients may be more susceptible to systemic toxicity due to their larger skin surface to body mass ratios [see Use in Specific Populations ( 8.4 )].

5.2 Allergic Contact Dermatitis

Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation, as observed with most topical products not containing corticosteroids. If irritation develops, discontinue hydrocortisone and institute appropriate therapy.

advertisement

6 ADVERSE REACTIONS

- Most frequent adverse reactions include burning, stinging, rash, papulovesicular rash, redness, itching, moderate paresthesia, and contact dermatitis.

To report SUSPECTED ADVERSE REACTIONS, contact PharmaDerm®, A division of Fougera Pharmaceuticals Inc. at 1-800-645-9833 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The most frequent adverse reactions reported for hydrocortisone during clinical trials were application site reactions, including burning in 4, stinging in 2, and moderate paresthesia in 1 out of 226 subjects.

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of hydrocortisone because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

These adverse reactions are as follows:

Skin and Subcutaneous Tissue Disorders: rash, papulovesicular rash

Application Site Reactions: dryness, erythema, pruritus, allergic contact dermatitis.

The following local adverse reactions are reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infections, skin atrophy, striae, and miliaria.

advertisement

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There is no clinical information on hydrocortisone use in pregnant women to inform any drug-associated risk for major birth defects and miscarriage. In animal reproduction studies, hydrocortisone probutate given by the subcutaneous route during the period of organogenesis was teratogenic at doses equal to or greater than 1 mg/kg/day in rats or 0.1 mg/kg/day in rabbits .

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

Effects on embryo-fetal development were evaluated in rats and rabbits following subcutaneous administration of hydrocortisone probutate during the period of organogenesis. hydrocortisone probutate was teratogenic in rats when given during the period of organogenesis at subcutaneous doses equal to or greater than 1 mg/kg/day (12 times the human average topical dose of hydrocortisone assuming 3% absorption and an application of 30 g/day on a 70 kg individual). Abnormalities included delayed ossification of the caudal vertebrae and other skeletal variations, cleft palate, umbilical hernia, edema, and exencephalia.

In rabbits, hydrocortisone probutate given by the subcutaneous route was teratogenic at doses equal to or greater than 0.1 mg/kg/day (2 times the human average topical dose of hydrocortisone assuming 3% absorption and an application of 30 g/day on a 70 kg individual). Fetal weight and survival were affected. Delayed ossification and increased incidences of malformations (skeletal abnormalities and cleft palate) were also noted.

No adverse effects were seen in rats following subcutaneous administration of up to 1 mg/kg/day of hydrocortisone probutate during the perinatal and postnatal period (12 times the human average topical dose of hydrocortisone assuming 3% absorption and an application of 30 g/day on a 70 kg individual).

8.2 Lactation

Risk Summary

There is no information on the presence of hydrocortisone probutate in breast milk, or on its effects on the breastfed infant or on milk production. It is not known whether topical administration of hydrocortisone could result in sufficient systemic absorption to produce detectable quantities in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for hydrocortisone and any potential adverse effects on the breastfed infant from hydrocortisone or from the underlying maternal condition.

Clinical Considerations

To minimize potential exposure to the breastfed infant via breast milk, use hydrocortisone on the smallest area of skin and for the shortest duration possible while breastfeeding.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing’s syndrome when they are treated with topical corticosteroids. They are therefore also at a greater risk of adrenal insufficiency during and/or after withdrawal of treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

advertisement

11 DESCRIPTION

hydrocortisone(hydrocortisone probutate) Cream, 0.1% contains hydrocortisone probutate, a synthetic corticosteroid. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents.

hydrocortisone probutate is a tasteless and odorless white crystalline powder practically insoluble in hexane or water, slightly soluble in ether, and very soluble in dichloromethane, methanol and acetone. Chemically, it is 11β,17,21-trihydroxypregn-4-ene-3,20-dione 17-butyrate 21-propionate. The structural formula is:

Molecular Formula: C28H40O7

Molecular Weight: 488.62

Each gram of hydrocortisone (hydrocortisone probutate) Cream, 0.1% contains: 1 mg of hydrocortisone probutate in a cream base of propylene glycol, white petrolatum, light mineral oil, stearyl alcohol, polysorbate 60, sorbitan monostearate, glyceryl monostearate, PEG-20 stearate, glyceryl stearate SE, methylparaben, butylparaben, citric acid, sodium citrate anhydrous, and purified water.

Structural Formula

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in corticosteroid responsive dermatoses is unknown

12.2 Pharmacodynamics

Vasoconstrictor Assay

Studies performed with hydrocortisone indicate that it is in the medium range of potency as demonstrated in vasoconstrictor trials in healthy subjects when compared with other topical corticosteroids. However, similar blanching scores do not necessarily imply therapeutic equivalence.

Hypothalamic-Pituitary-Adrenal Axis Suppression

In an open label HPA axis suppression trial, 19 adult subjects (ages 23 to 82 years) with atopic dermatitis or plaque psoriasis covering greater than 20% Body Surface Area (BSA) were treated with hydrocortisone twice daily for 21 days and were assessed for HPA axis suppression. At baseline, the mean disease BSA involvement was 36%. The criterion for HPA axis suppression was a serum cortisol level of less than or equal to 18 micrograms per deciliter at 30-minutes after cosyntropin stimulation. Of these subjects, 15 were considered evaluable with respect to their adrenal axis function post-treatment. One of the evaluable subjects (6.7%) showed laboratory evidence of suppression on Day 22. This subject had psoriasis covering 48% of BSA at baseline and was reported to have received 98% of the twice-daily applications of hydrocortisone over the 21 day treatment period. It is not known if this subject had recovery of adrenal function because follow-up testing was not performed.

12.3 Pharmacokinetics

The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Use of occlusive dressings with hydrocortisone for up to 24 hours has not been shown to increase penetration; however, occlusion of hydrocortisone for 96 hours does markedly enhance penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term studies in animals have been performed to evaluate the carcinogenic potential of hydrocortisone probutate.

hydrocortisone probutate revealed no evidence of mutagenic or clastogenic potential based on the results of an in vitro genotoxicity test (Ames assay) and an in vivo genotoxicity test (mouse micronucleus assay).

Effects on fertility and early embryonic development were evaluated in rats following subcutaneous administration of up to 0.4 mg/kg/day hydrocortisone probutate (5 times the human average topical dose of hydrocortisone assuming 3% absorption and an application of 30 g/day on a 70 kg individual) prior to and during mating and through early pregnancy. No treatment related effects on fertility or mating parameters were noted in this study.

16 HOW SUPPLIED/STORAGE AND HANDLING

hydrocortisone, a white to off-white opaque cream is supplied as follows:

45 g tubes NDC 10337-153-46

80 g tubes NDC 10337-153-80

Store at 20° to 25°C (68° to 77°F).

17 PATIENT COUNSELING INFORMATION

Advise the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information).

Inform patients and/or caregivers of the following:

  • Discontinue therapy when control is achieved unless directed otherwise by the physician.
  • If no improvement is seen within two weeks, contact the physician.
  • Avoid contact with the eyes.
  • Do not use with occlusive dressing unless directed by the physician.
  • Report any signs or symptoms of local or systemic adverse reactions to the physician.
  • Do not treat diaper dermatitis. Do not apply hydrocortisone in the diaper area as diapers or plastic pants may constitute occlusive dressings.
  • Do not use on the face, underarms, or groin areas unless directed by the physician.
  • Advise a woman to use hydrocortisone on the smallest area of skin and for the shortest duration possible while breastfeeding.

Manufactured by:

PharmaDerm®

A division of Fougera

PHARMACEUTICALS INC.

Melville, New York 11747 www.pharmaderm.com


PATIENT INFORMATION

hydrocortisone® (pan-del)

(hydrocortisone probutate)

cream


Important: hydrocortisone is for use on skin only (topical). Avoid using hydrocortisone near or around your eyes.


What is hydrocortisone?

hydrocortisone is a prescription corticosteroid medicine used on the skin (topical) for the relief of inflammation and itching caused by certain skin conditions in people 18 years of age or older.

It is not known if hydrocortisone is safe and effective in children.


Before using hydrocortisone tell your healthcare provider about all of your medical conditions, including if you:

- have adrenal gland problems

- have liver problems

- have diabetes

- have thinning skin (atrophy) at the site to be treated.

- are pregnant or plan to become pregnant. It is not known if hydrocortisone will harm your unborn baby.

- are breastfeeding or plan to breastfeed. It is not known if hydrocortisone can pass into your breast milk and harm your baby.

  • o If you breastfeed during treatment with hydrocortisone, clean the treated area of skin on and near your breast, and your nipple before breastfeeding. This will help prevent contact of hydrocortisone with your baby’s skin.
  • o You should use hydrocortisone on the smallest area of skin and for the shortest time possible while breastfeeding.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.


How should I use hydrocortisone?

- Use hydrocortisone exactly as your healthcare provider tells you to use it.

- Apply a thin film to the affected skin area. Gently rub hydrocortisone into your skin until it disappears.

- Tell your healthcare provider if your symptoms do not improve after 2 weeks of treatment.

- Do not bandage, cover, or wrap the treated area unless your healthcare provider tells you to.

- Do not apply hydrocortisone in the diaper area or use with plastic pants.

- Do not use hydrocortisone on your face, underarms (armpits) or groin areas unless your healthcare provider tells you to.

- Wash your hands after applying hydrocortisone, unless your hands are being treated.


What are possible side effects with hydrocortisone?

hydrocortisone may cause serious side effects, including:

- hydrocortisone can pass through your skin and may cause adrenal gland problems. This is more likely to happen if you use hydrocortisone for too long, use it over a large treatment area, use it with other topical medicines that contain corticosteroids, cover the treated area, or have liver failure. Your healthcare provider may do blood tests to check your adrenal gland function during and after treatment with hydrocortisone.

- Skin problems, including skin reactions or thinning of your skin (atrophy), skin infections, and allergic reactions (allergic contact dermatitis) at the treatment site. Tell your healthcare provider if you get any skinreactions such as pain, tenderness, swelling, or healing problems.

The most common side effects of hydrocortisone include burning and stinging and moderate tingling or prickling feeling.

These are not all the possible side effects with hydrocortisone. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


How should I store hydrocortisone?

- Store hydrocortisone between 68°F to 77°F (20°C to 25°C).

Keep hydrocortisone and all medicines out of the reach of children.


General information about the safe and effective use of hydrocortisone.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use hydrocortisone for a condition for which it was not prescribed. Do not give hydrocortisone to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about hydrocortisone that is written for health professionals.


What are the ingredients in hydrocortisone?

Active ingredient: hydrocortisone probutate

Inactive ingredients: propylene glycol, white petrolatum, light mineral oil, stearyl alcohol, polysorbate 60, sorbitan monostearate, glyceryl monostearate, PEG-20 stearate, glyceryl stearate SE, methylparaben, butylparaben, citric acid, sodium citrate anhydrous, and purified water.

Manufactured by:PharmaDerm® A division of Fougera PHARMACEUTICALS INC. Melville, New York 11747

For more information, go to www.pharmaderm.com or call 1-800-645-9833.

  • This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: 01/2017

PharmaDerm®

NDC 10337-153-80

hydrocortisone®

(hydrocortisone probutate) Cream, 0.1%

FOR DERMATOLOGIC USE ONLY.

NOT FOR OPHTHALMIC USE.

Rx only

80 g

carton

Hydrocortisone available forms, composition, doses:

Price
A-hydrocort 100 mg vial2.42 USD
Ala Scalp 2% Lotion 29.6ml Bottle30.99 USD
Ala-cort 1% cream0.43 USD
Ala-scalp hp 2% lotion1.03 USD
Anusol-HC 2.5% Cream 30 gm Tube106.45 USD
Anusol-hc 2.5% cream3.45 USD
Aquanil hc 1% lotion0.12 USD
Balneol lotion0.18 USD
Beta hc 1% lotion0.14 USD
Colocort 100 mg enema0.21 USD
Colocort 100 mg/60ml Enema 60ml Bottle13.15 USD
Cortaid 1% spray0.1 USD
Cortamed 2.5 % Ointment5.67 USD
Cortef 10 mg tablet0.55 USD
Cortef 20 mg tablet0.9 USD
Cortef 5 mg tablet0.45 USD
Cortenema (100 mg/60Ml) 100 mg/enm Enema6.96 USD
Cortenema 100 mg enema0.21 USD
Corticaine 0.5% cream0.37 USD
Cortifoam 10 % Foam6.14 USD
Cortifoam 10% aerosol9.35 USD
Cortifoam 90 mg Foam 15 gm Can239.99 USD
Cortisporin 0.5-0.5-10000 Cream 7.5 gm Tube54.37 USD
Cortisporin 1% Ointment 15 gm Tube75.09 USD
Cortisporin 3.5-10000-1 Solution 10ml Bottle84.33 USD
Cortisporin 3.5-10000-1 Suspension 10ml Bottle79.55 USD
Cortisporin ear suspension7.86 USD
Cortisporin eye drops19.74 USD
Cortisporin-tc ear susp8.3 USD
Cortizone-10 1% spray0.14 USD
Cortoderm Mild 0.5 % Ointment0.15 USD
Cortoderm Regular 1 % Ointment0.04 USD
Cream; Topical; Hydrocortisone 0.5%
Cream; Topical; Hydrocortisone 1%
Cream; Topical; Hydrocortisone 2.5%
Cream; Topical; Hydrocortisone Acetate 1%
Cream; Topical; Hydrocortisone Acetate 2.5%
Cream; Topical; Hydrocortisone Butyrate 0.1%
Emo-Cort 1 % Cream0.19 USD
Emo-Cort 1 % Lotion0.18 USD
Emo-Cort 2.5 % Cream0.26 USD
Emo-Cort 2.5 % Lotion0.23 USD
Emo-Cort Scalp 2.5 % Lotion0.22 USD
First hydrocort 10% gel1.18 USD
Hycort (100 mg/60Ml) 100 mg/enm Enema5.79 USD
Hyderm 0.5 % Cream0.18 USD
Hyderm 1 % Cream0.04 USD
Hydrocortisone 0.5% Cream 28.35 gm Tube11.99 USD
Hydrocortisone 0.5% cream0.08 USD
Hydrocortisone 1% Cream 15 gm Tube11.99 USD
Hydrocortisone 1% Cream 28 gm Tube11.99 USD
Hydrocortisone 1% Lotion 118ml Bottle15.99 USD
Hydrocortisone 1% cream0.08 USD
Hydrocortisone 10 mg tablet0.52 USD
Hydrocortisone 100 mg/60ml Enema 60ml Bottle12.6 USD
Hydrocortisone 2.5% Cream 30 gm Tube13.67 USD
Hydrocortisone 2.5% Lotion 59 gm Bottle55.61 USD
Hydrocortisone 2.5% Lotion 59ml Bottle47.47 USD
Hydrocortisone 2.5% Ointment 28.35 gm Tube13.68 USD
Hydrocortisone 2.5% cream0.53 USD
Hydrocortisone 2.5% lotion0.6 USD
Hydrocortisone 20 mg tablet0.32 USD
Hydrocortisone 5 mg tablet0.38 USD
Hydrocortisone Ace-Pramoxine 2.5-1% Cream 28.35 gm Tube64.75 USD
Hydrocortisone Acetate 1-1% Ointment 30 gm Tube11.99 USD
Hydrocortisone Acetate 12 25 mg Suppository Box15.01 USD
Hydrocortisone Butyrate 0.1% Cream 45 gm Tube49.43 USD
Hydrocortisone Sod. Succinate 1 g/vial9.01 USD
Hydrocortisone Sod. Succinate 100 mg/vial2.1 USD
Hydrocortisone Sod. Succinate 250 mg/vial3.56 USD
Hydrocortisone Sod. Succinate 500 mg/vial5.34 USD
Hydrocortisone Valerate 0.2% Cream 15 gm Tube19.99 USD
Hydrocortisone Valerate 0.2% Cream 45 gm Tube33.99 USD
Hydrocortisone Valerate 0.2% Cream 60 gm Tube44.99 USD
Hydrocortisone Valerate 0.2% Ointment 15 gm Tube30.56 USD
Hydrocortisone Valerate 0.2% Ointment 45 gm Tube48.73 USD
Hydrocortisone Valerate 0.2% Ointment 60 gm Tube56.74 USD
Hydrocortisone acet powder3.15 USD
Hydrocortisone buty 0.1% cream1.31 USD
Hydrocortisone hemisucc powder9.9 USD
Hydrocortisone plus 12 1% crm0.12 USD
Hydrocortisone powder5.19 USD
Hydrocortisone ss 250 mg vial3.5 USD
Hydrocortisone val 0.2% cream2.07 USD
Hydroval 0.2 % Cream0.13 USD
Hydroval 0.2 % Ointment0.13 USD
Hytone 1% cream0.17 USD
Hytone 2.5% cream1.46 USD
Injectable; Injection; Hydrocortisone 1 g
Injectable; Injection; Hydrocortisone Acetate 25 mg / ml
Injectable; Injection; Hydrocortisone Acetate 25 mg; Lidocaine Hydrochloride 5 mg / ml
Injectable; Injection; Hydrocortisone Acetate 50 mg / ml
Injectable; Injection; Hydrocortisone Sodium Phosphate 50 mg / ml
Injectable; Injection; Hydrocortisone Sodium Succinate 1 g
Injectable; Injection; Hydrocortisone Sodium Succinate 100 mg
Injectable; Injection; Hydrocortisone Sodium Succinate 250 mg
Injectable; Injection; Hydrocortisone Sodium Succinate 500 mg
Lanacort 1% cool creme0.18 USD
Locoid 0.1% Cream 15 gm Tube67.49 USD
Locoid 0.1% Cream 45 gm Tube183.83 USD
Locoid 0.1% Ointment 15 gm Tube62.04 USD
Locoid 0.1% Ointment 45 gm Tube174.86 USD
Locoid 0.1% Solution 20ml Bottle79.28 USD
Locoid 0.1% Solution 60ml Bottle233.15 USD
Locoid 0.1% cream3.92 USD
Locoid 0.1% lipocream4.3 USD
Locoid Lipocream 0.1% Cream 15 gm Tube85.41 USD
Locoid Lipocream 0.1% Cream 45 gm Tube200.98 USD
Locoid Lipocream 0.1% Cream 60 gm Tube335.36 USD
Lotion; Topical; Hydrocortisone 0.5%
Lotion; Topical; Hydrocortisone 1%
Lotion; Topical; Hydrocortisone 2.5%
Ointment; Ophthalmic; Hydrocortisone 1%
Ointment; Ophthalmic; Hydrocortisone Acetate 0.5%
Ointment; Topical; Hydrocortisone 0.5%
Ointment; Topical; Hydrocortisone 1%
Ointment; Topical; Hydrocortisone 2.5%
Ointment; Topical; Hydrocortisone Acetate 1%
Orabase plain paste0.77 USD
Orabase-b 20% gel0.55 USD
Pandel 0.1% Cream 15 gm Tube138.56 USD
Pandel 0.1% Cream 45 gm Tube161.37 USD
Pandel 0.1% cream4.34 USD
Preparation h 1% cream0.24 USD
Prevex Hc 1 % Occlusive Cream0.3 USD
Procto-kit 1% cream1.08 USD
Proctocort 1% Cream 28.35 gm Tube127.51 USD
Proctocort 1% cream4.37 USD
Proctocream-hc 2.5% cream2.17 USD
Proctofoam2.89 USD
Proctofoam HC 1-1% Foam 10 gm Can81.9 USD
Proctofoam-hc foam6.77 USD
Proctosol-hc 2.5% cream0.89 USD
Proctozone-hc 2.5% cream0.83 USD
Sarna Hc 1 % Lotion0.1 USD
Sarna Hc 2.5 % Lotion0.2 USD
Scalpicin 3% liquid0.12 USD
Slender cortisol capsule0.12 USD
Solu-Cortef 1 g/vial17.55 USD
Solu-Cortef 100 mg/vial4.07 USD
Solu-Cortef 250 mg/vial7.05 USD
Solu-Cortef 500 mg/vial10.47 USD
Solu-cortef (pf) 100 mg vial4.85 USD
Solu-cortef (pf) 250 mg vial8.58 USD
Solu-cortef 100 mg vial4.63 USD
Tablets; Oral; Hydrocortisone 10 mg
Tablets; Oral; Hydrocortisone 20 mg
Tablets; Oral; Hydrocortisone 5 mg
Texacort 2.5% Solution 30ml Bottle85.41 USD
Tucks hydrocortisone ointment0.24 USD
Uniderm moisturizer0.05 USD
Westcort 0.2% Cream 15 gm Tube25.99 USD
Westcort 0.2% Ointment 15 gm Tube50.99 USD
Westcort 0.2% Ointment 45 gm Tube46.97 USD
Westcort 0.2% Ointment 60 gm Tube55.0 USD
Westcort 0.2% cream1.17 USD

Indications and Usages:

ATC codes:


ICD-10 codes:


Hydrocortisone destination | category:


advertisement

Drugs with same active ingredients (Pharmaceutical companies):


References

  1. Dailymed."HYDROCORTISONE SPRAY [21ST CENTURY HEALTHCARE INC.]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  2. Dailymed."CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  3. "hydrocortisone". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Hydrocortisone?

Depending on the reaction of the Hydrocortisone after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Hydrocortisone not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Hydrocortisone addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

advertisement

Review

sdrugs.com conducted a study on Hydrocortisone, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Hydrocortisone consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reported useful

No survey data has been collected yet

Visitor reported side effects

No survey data has been collected yet

Visitor reported price estimates

No survey data has been collected yet

Two visitors reported frequency of use

How often in a day do you take the medicine?
Are you taking the Hydrocortisone drug as prescribed by the doctor?

Few medications can be taken Twice in a day more than prescribed when the doctor's advice mentions the medicine can be taken according to frequency or severity of symptoms. Most times, be very careful and clear about the number of times you are taking the medication. The report of sdrugs.com website users about the frequency of taking the drug Hydrocortisone is mentioned below.
Visitors%
Twice in a day1
50.0%
Once in a day1
50.0%

One visitor reported doses

What is the dose of Hydrocortisone drug you are taking?
According to the survey conducted among sdrugs.com website users, the maximum number of people are using the following dose 11-50mg. Few medications come in only one or two doses. Few are specific for adult dose and child dose. The dose of the medicine given to the patient depends on the severity of the symptom/disease. There can be dose adjustments made by the doctor, based on the progression of the disease. Follow-up is important.
Visitors%
11-50mg1
100.0%

One visitor reported time for results

What is the time duration Hydrocortisone drug must be taken for it to be effective or for it to reduce the symptoms?
Most chronic conditions need at least some time so the dose and the drug action gets adjusted to the body to get the desired effect. The stastistics say sdrugs.com website users needed 2 weeks to notice the result from using Hydrocortisone drug. The time needed to show improvement in health condition after using the medicine Hydrocortisone need not be same for all the users. It varies based on other factors.
Visitors%
2 weeks1
100.0%

Visitor reported administration

No survey data has been collected yet

Five visitors reported age

Visitors%
6-151
20.0%
30-451
20.0%
16-291
20.0%
> 601
20.0%
1-51
20.0%

Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 1 here

The information was verified by Dr. Arunabha Ray, MD Pharmacology

© 2002 - 2021 "sdrugs.com". All Rights Reserved